Evidence map›Paper›PMID 31046695›Full record

ArticleBMC infectious diseases2019

The role of point-of-care viral load monitoring in achieving the target of 90% suppression in HIV-infected patients in Nigeria: study protocol for a randomized controlled trial.

Seema T Meloni, Oche Agbaji, Charlotte A Chang, Patricia Agaba, Godwin Imade, Stephen Oguche, Ahmed Mukhtar, Kiren Mitruka, Mackenzie Hurlston Cox, Aaron Zee and 1 more

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in BMC infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03533868 (Reaching 90% Target of HIV Viral Suppression), which is not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03533868 nacompletednot on this map

Reaching 90% Target of HIV Viral Suppression: The Role of Point-of-Care Viral Load Monitoring in Resource-Constrained Settings in Nigeria

TypeinterventionalSponsorHarvard School of Public Health (HSPH)Ran2018 to 2021Enrolled543ConditionsHIV/AIDSArmsPoint-of-care viral load monitoring test
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Clinical Outcomes in a Randomized Controlled Trial Comparing Point-of-Care With Standard Human Immunodeficiency Virus (HIV) Viral Load Monitoring in Nigeria.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Trial
  2. Timeliness of Point-of-Care Viral Load Results Improves Human Immunodeficiency Virus Monitoring in Nigeria.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Seema T MeloniDepartment of Immunology & Infectious Diseases, Harvard T. H. Chan School of Public Health, 651 Huntington Avenue, Boston, MA, USA.
Oche AgbajiJos University Teaching Hospital, Bauchi Road, PMB, Jos, Plateau State, 2076, Nigeria.
Charlotte A ChangDepartment of Immunology & Infectious Diseases, Harvard T. H. Chan School of Public Health, 651 Huntington Avenue, Boston, MA, USA.
Patricia AgabaJos University Teaching Hospital, Bauchi Road, PMB, Jos, Plateau State, 2076, Nigeria.
Godwin ImadeJos University Teaching Hospital, Bauchi Road, PMB, Jos, Plateau State, 2076, Nigeria.
Stephen OgucheJos University Teaching Hospital, Bauchi Road, PMB, Jos, Plateau State, 2076, Nigeria.
Ahmed MukhtarCenters for Disease Control and Prevention, Plot 1075 Diplomatic Drive, Abuja, Nigeria.
Kiren MitrukaCenters for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA, USA.
Mackenzie Hurlston CoxCenters for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA, USA.
Aaron ZeeCenters for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA, USA.
Phyllis KankiDepartment of Immunology & Infectious Diseases, Harvard T. H. Chan School of Public Health, 651 Huntington Avenue, Boston, MA, USA. pkanki@hsph.harvard.edu.ORCID http://orcid.org/0000-0003-4739-4572
Jos University Teaching Hospital · NGCenters for Disease Control and Prevention · USHarvard University · USNigeria Centre for Disease Control · NG

Funding

Northwestern University AITRPD43TW007995 · FIC · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MURPHY, ROBERT LEO · 2008 to 2012
$1.6M
ACL HHS U01GH002109CGH CDC HHS U01 GH002109CGH CDC HHS U01GH002109FIC NIH HHS D43 TW007995
6 · The paper itself

Abstract

backgroundThe Joint United Nations Programme on HIV/AIDS 90-90-90 goal envisions 90% of all people receiving antiretroviral therapy to be virally suppressed by 2020. Implied in that goal is that viral load be quantified for all patients receiving treatment, which is a challenging undertaking given the complexity and high cost of standard-of-care viral load testing methods. Recently developed point-of-care viral load testing devices offer new promise to improve access to viral load testing by bringing the test closer to the patient and also returning results faster, often same-day. While manufactures have evaluated point-of-care assays using reference panels, empiric data examining the impact of the new technology against standard-of-care monitoring in low- and middle-income settings are lacking. Our goal in this trial is to compare a point-of-care to standard-of-care viral load test on impact on various clinical outcomes as well to assess the acceptability and feasibility of using the assay in a resource-limited setting.

methodsUsing a two-arm randomized control trial design, we will enroll 794 patients from two different HIV treatment sites in Nigeria. Patients will be randomized 1:1 for point-of-care or standard-of-care viral load monitoring (397 patients per arm). Following initiation of treatment, viral load will be monitored at patients' 6- and 12-month follow-up visits using either point-of-care or standard-of-care testing methods, based on trial assignment. The monitoring schedule will follow national treatment guidelines. The primary outcome measure in this trial is proportion of patients with viral suppression at month 12 post-initiation of treatment. The secondary outcome measures encompass acceptability, feasibility, and virologic impact variables. DISCUSSION: This clinical trial will provide information on the impact of using point-of-care versus standard-of-care viral load testing on patient clinical outcomes; the study will also supply data on the acceptability and feasibility of point-of-care viral load monitoring in a resource-limited setting. If this method of testing is acceptable and feasible, and also superior to standard of care, the results of the trial and the information gathered will inform future scaled implementation and further optimization of the clinic-laboratory network that is critical for monitoring achievement of the 90-90-90 goals.

trial registrationUS National Institutes of Health Clinical Trials.gov: NCT03533868 . Date of Registration: 23 May 2018. Protocol Version: 10. Protocol Date: 30 March 2018.

Indexed as

Point-of-Care SystemsViral LoadAdolescentAdultAnti-Retroviral AgentsChildHIVHIV InfectionsHumansNigeriaRandomized Controlled Trials as TopicAnti-Retroviral AgentsAdherenceAntiretroviral therapyHIVNigeriaPoint-of-careRetentionViral load

Identifiers

PMID31046695
PMCPMC6495593
OpenAlexW2947025548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.